NCT03759366 / 2016-001384-37: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) |
|
|
| Completed | 3 | 11 | Europe, Japan, US | Eculizumab | Alexion Pharmaceuticals, Inc. | Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized | 01/22 | 11/23 | | |
